Author: admin

Epilepsy Market Size in the 7MM was ~USD 9 Billion in 2023, estimated DelveInsight

Epilepsy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Epilepsy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Epilepsy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Epilepsy Market with DelveInsight’s In-Depth Report @ Epilepsy Market Size

 

Key Takeaways from the Epilepsy Market Report

  • In the 7MM, the total diagnosed prevalent cases of epilepsy were nearly 7 million in 2023, which is expected to increase at a CAGR of 0.4% by 2034.
  • In the US, the total diagnosed prevalent cases of epilepsy were approximately 3.3 million in 2023, of which nearly 14% of cases were diagnosed in children and 86% in adults; the total cases of epilepsy are expected to increase by 2034.
  • In 2023, the diagnosed prevalent cases in the EU4 and the UK comprised nearly 1.3 million male cases and 1.5 million female cases. These numbers are expected to rise throughout the study period.
  • In 2023, among EU4 and the UK, Germany had the highest number of cases of epilepsy, i.e., 735 thousand, of which nearly 74% of the cases were focal epileptic seizures, 18% were generalized epileptic seizures, while 8% of the cases were other determined or undetermined epileptic seizures.
  • Among the 7MM, in 2023, Japan accounted for the second highest diagnosed prevalent cases of epilepsy, i.e., 890 thousand cases, these cases are expected to change during the study period.
  • In Japan, among the other types of epilepsies and associated diseases, the highest cases were found in drug-resistant epilepsy/refractory cases, i.e., 82 thousand followed by photosensitivity and childhood absence epilepsy with equal cases, i.e., 44 thousand, in 2023. These cases are expected to change by 2034.
  • The leading Epilepsy Companies such as Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
  • Promising Epilepsy Therapies such as Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.

 

Stay ahead in the Epilepsy Therapeutics Market with DelveInsight’s Strategic Report @ Epilepsy Market Outlook

 

Epilepsy Epidemiology Segmentation in the 7MM

  • Total Diagnosed Prevalent Cases
  • Gender-specific Diagnosed Prevalent Cases
  • Diagnosed Prevalent Cases of Epilepsy Based on Seizure Type
  • Diagnosed Cases of Other Types of Epilepsies and Associated Diseases

 

Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Prevalence

 

Epilepsy Treatment Market

The Epilepsy treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient’s condition and the severity of the case. Epilepsy treatment involves various drug classes to control seizures, including sodium channel blockers (e.g., phenytoin, lamotrigine), which stabilize neuronal activity by inhibiting abnormal electrical impulses. Calcium channel blockers (e.g., ethosuximide) are effective for absence seizures, while GABAergic agents (e.g., valproate, benzodiazepines) enhance inhibitory neurotransmission to reduce seizure frequency.

 

Epilepsy Marketed Drugs

  • LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
  • EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals
  • XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical
  • AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis

 

Epilepsy Emerging Drugs

  • XEN1101/Azetukalner: Xenon Pharmaceuticals
  • Soticlestat (TAK-935): Takeda/Ovid Therapeutics

 

Get In-Depth Knowledge on Epilepsy Market Trends and Forecasts with DelveInsight @ Epilepsy Treatment Market

 

Epilepsy Market Outlook

The treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient’s condition and the severity of the case.

 

Scope of the Epilepsy Market Report

  • Coverage- 7MM
  • Epilepsy Companies- Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
  • Epilepsy Therapies- Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.
  • Epilepsy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Epilepsy Market Report @ Epilepsy Market Drivers and Barriers

 

Table of Content

1 Key Insights

2 Report Introduction

3 Epilepsy Market Overview at a Glance

4 Methodology of Epilepsy Epidemiology and Market

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Epilepsy Patient Journey

9 Epilepsy Epidemiology and Patient Population

10 Epilepsy Marketed Drugs

11 Epilepsy Emerging Drugs

12 Epilepsy: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Epilepsy Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Market Size in the 7MM was ~USD 9 Billion in 2023, estimated DelveInsight

Creative Biolabs Launches Solutions for Antisense Oligonucleotide Therapy Research

Antisense oligonucleotides are becoming increasingly important in the field of therapeutics, and Creative Biolabs is dedicated to providing high-quality antisense oligonucleotide services and products tailored to our clients’ needs.

New York, USA – November 14, 2024 – In recent years, antisense oligonucleotides (ASO) therapy has emerged as a promising approach in the treatment of various genetic disorders. ASOs are short, synthetic strands of nucleic acids designed to specifically bind to messenger RNA (mRNA), resulting in the modulation of gene expression, and providing new avenues for therapeutic interventions, particularly in the realm of rare diseases and neurodegenerative disorders. In light of this ongoing advancement, Creative Biolabs is proud to announce the launch of its comprehensive solutions tailored for antisense oligonucleotide therapy research.

At a gene therapy-related exhibition, scientists from Creative Biolabs introduced products and services related to antisense oligonucleotides, with a particular emphasis on antisense oligonucleotide screening.

“Efficient ASO screening enables researchers to identify the most effective oligonucleotide sequences for their target genes. Our high-throughput workflow can simultaneously test thousands of ASOs in vitro and finally select expected candidate ASOs.” said a scientist at Creative Biolabs. “The synthesis of high-quality antisense oligonucleotides is another crucial step.”

Creative Biolabs offers a suite of antisense oligonucleotide synthesis and screening services for a variety of purposes.

“We enabled the facilities equipped with high-end equipment which can produce ASOs of high purity and specificity. There are options for our clients such as the provision of phosphorothioate backbones for their ASOs and other conjugations for better stability and delivery,” said the scientist.

Throughout the entire development process, the company adheres to strict quality control measures, from the design phase to the purification stage. Their team utilizes advanced analytical techniques such as HPLC, mass spectrometry, and sequencing to ensure the identity and integrity of each oligonucleotide.

“We found a scientist from Japan recently explored the use of ASOs to reduce the expression of aSyn and improve symptoms in a mouse model of Parkinson’s disease. This is a good news for us. The field is rapidly evolving, and our company is committed to staying at the forefront of this research and continuously improving our ASO synthesis services to meet these emerging needs,” added the scientist.

Learn more about antisense oligonucleotide solutions and related products, please visit https://www.creative-biolabs.com/gene-therapy.

About Creative Biolabs

Creative Biolabs is at the forefront of addressing the demands of specialized solutions for ASOs, providing researchers with the tools required to advance their work in antisense oligonucleotide therapy. Aiming at creativity, high standards of quality, and support, Creative Biolabs is giving more power to scientists in their quest to use gene therapy to discover new elements.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/gene-therapy

Breakthrough HIV and SARS-CoV-2 Treatments via Key Biotech Merger Agreement, Plus Generative AI Chatbots for 24/7 Support of Investors and Medicinal Professionals: 1606 Corp (Stock Symbol: CBDW)

• Leading Biotechnology Innovator Specializing in AI Chatbot Solutions for Early Drug Discovery, Infectious Disease and Neurodegenerative Disease Research. 

• Focus on Developing Therapeutic Solutions by Leveraging Human Immune-B Cells for a Cutting-Edge Approach to Highly Effective Treatments.

• Strategic Investment Plan Demonstrating Commitment to Advancing Technological Capabilities and Expanding Reach in the AI Sector.

• Launch of Sutra (TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research. 

• Strategic Investment Target Adnexus Biotechnologies Merges with Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments.

• AI Platform Confirmed Decades of Work and Added New Targets for Monoclonal Antibodies with Independent Validation of Their Potential from Collaborators.

• Growing IP Portfolio Including Patents, Trademarks and Trade Secrets. 

• With a Database of 19 Viruses, the Sutra™ AI Platform Can Predict and Help Prevent Future Pandemics. 

• Harnessing the Power of AI to Revolutionize Drug Repurposing, Offering a Cost-Effective Alternative to Developing New Drugs from the Ground Up. 

1606 Corp. (OTC: CBDW) stands at the forefront of technological innovation, particularly in AI Chatbots. The CBDW mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. CBDW is dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.

CBDW is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease, and neurodegenerative disease research. CBDW proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. 

CBDW Generative AI Chatbots can provide instant, round-the-clock support, guiding potential investors through the company. Queries about dosage, usage, legality, while offering personalized recommendations based on individual preferences. Moreover, CBDW chatbots can handle multiple interactions simultaneously, ensuring no potential or existing investor feels neglected due to long response times. They also collect valuable data on investor preferences and behaviors, allowing companies to tailor their communication strategies more effectively. In the investor relations industry, where transparency and timely information are paramount, CBDW chatbots can provide up-to-date details on earnings reports, stock performance and company news. This immediate access to information builds confidence with investors, encouraging them to make informed decisions. 

The global artificial intelligence market has seen remarkable growth, valued at $428 billion in 2022 and projected to reach $2.25 trillion by 2030. With a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%, AI’s global impact is undeniable, with as many as 97 million individuals expected to work in the AI sector by 2025, according to fortunebusinessinsights.com

CBDW Target for Strategic Investment Adnexus Biotechnologies Merges with Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments

On November 12th CBDW acquisition target Adnexus Biotechnologies Inc. is revealed completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies’ significant resources and expertise. The combination of resources and expertise significantly enhance the research capabilities of CBDW HIV and SARS-CoV-2 research.

Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics’ leading-edge assets. This strategic merger combines Adnexus’s state-of-the-art AI-driven drug discovery platform with Sanctum’s innovative long-acting HIV capsid inhibitor and Adnexus’s short-acting anti-HIV monoclonal antibodies. Together, these therapies offer a potent, dual-action approach that enhances treatment efficacy, reduces the risk of viral resistance, and provides a promising new option for HIV patients.

The acquisition further strengthens the CBDW position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases. With Sanctum’s advanced inhibitors and expertise in navigating the FDA regulatory landscape, CBDW will be uniquely positioned to accelerate the development of high-impact therapies.

Adnexus has recently executed a Letter of Intent with the CBDW for a strategic investment by the Company for 5% of Adnexus. The LOI terminates on November 27, 2024 and has an option to extend.

Unveils Sutra (TM) is a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research

On October 1st CBDW announced its new AI Empowered Drug Discovery Platform, Sutra™.

The CBDW Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their potential from collaborators. CBDW AI algorithms have identified several promising drug candidates. CBDW has identified a target in the mitochondrial metabolism that has a role in oncology. CBDW then adds them to an ever-growing IP portfolio, including patents, trademarks, and trade secrets, enhancing its competitive advantage and potential for future revenue. The success and validation of the CBDW Sutra™ AI platform for AI-discovered drugs are testaments to its capabilities and the future it promises.

CBDW is dedicated to pushing the boundaries of drug discovery with its AI Drug Discovery (AIDD) player, Sutra™. With the CBDW AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules. 

With a database of 19 viruses, the CBDW Sutra™ AI platform can predict and help prevent future pandemics. With access to a curated library of 8 million molecules, the CBDW platform makes possible the discovery of new drugs that precisely target neutralizable epitopes on viruses to enhance the potency and efficacy of existing therapies. The CBDW Sutra™ team’s unwavering dedication to leveraging microbiome samples to identify new biomarkers for neurodegenerative diseases instills hope for future medical breakthroughs.

CBDW harnesses the power of AI to revolutionize drug repurposing, offering a cost-effective alternative to developing new drugs from the ground up. Drug repurposing involves identifying potential new applications for existing compounds, which can be time-consuming and labor-intensive. However, AI algorithms can analyze existing drug databases and identify potential new applications for these compounds in a fraction of the time, making it a game-changer in the pharmaceutical industry. CBDW is exploring synergizing AI with suitable linkers between antibodies and drugs to promote multi-drug combinations. This approach will bring new therapeutics to market with more substantial impacts than combination therapies and address unmet medical needs, expediting drug discovery and regulatory approvals.

For more information on $CBDW visit: https://www.adnexusbiotech.com and https://cbdw.ai/

• Please verify and update the Website under media contact details.

Media Contact
Company Name: 1606 Corp.
Contact Person: Gaurav Chandra, CEO
Email: Send Email
Phone: (602) 481-1544
Address:2425 East Camelback Road Suite 150
City: Phoenix
State: AZ 8501
Country: United States
Website: https://www.adnexusbiotech.com

From Pioneer to Leader: Chery Drives Global Green Development

Recently, Chery officially launched its global nature conservation partnership with International Union for Conservation of Nature (IUCN). This milestone marks an important step for Chery in environmental protection and sustainable development. In addition to its close collaboration with IUCN, Chery has also established the ESG Global Community, joining forces with global distributors, suppliers, customers, media, and international public welfare organizations. The community aims to pool collective efforts to promote global sustainable development and environmental protection.

Partnering with IUCN for the “Cherish the Nature” Journey

In a time when global environmental issues and ecological crises are increasingly pressing, every responsible enterprise and institution should assume the duty of protecting the planet and promoting sustainable development. Against this backdrop, Chery and International Union for Conservation of Nature (IUCN) have announced a collaborative effort to launch the global “Cherish the Nature” initiative, aiming to address global environmental challenges such as water scarcity, marine ecosystem degradation, and biodiversity loss through deeper international cooperation, thus contributing to global sustainable development goals.

The partnership between Chery and IUCN not only underscores Chery’s steadfast commitment to the global environmental cause but also reflects its social responsibility and leadership in the industry. “Chery is not only reducing its environmental footprint but also advancing ecological sustainability by investing in technological innovation and promoting green solutions,” noted Yin Tongyue, Chairman of Chery Group. Both parties agree that, in the face of global environmental issues, only through transnational and cross-industry collaboration can we amass the powerful momentum needed to protect the planet.

To raise public awareness about environmental protection, Chery and IUCN have jointly planned a unique ecological cycling event. This event not only embodies the principles of environmental protection but also provides a valuable opportunity to promote a green lifestyle to the public. Cycling through natural landscapes, participants will raise awareness about the importance of environmental protection, advocate for low-carbon travel, and help safeguard our beautiful, shared home.

The launch of the “Cherish the Nature” project marks an important step in the collaborative journey of Chery and IUCN toward a sustainable future. Moving forward, both parties will continue to deepen their cooperation, promote more environmental projects, and contribute wisdom and strength to the global environmental cause.

Actively Practicing ESG to Build a Global Community of Shared Interests

After 27 years of development, Chery has grown from nothing, advancing from importing and learning to self-innovation. As shown in Fortune magazine, Chery has made it into the Fortune Global 500 for the first time, expanding its reach into global markets. As it progresses, Chery looks beyond the present toward the future. “A truly global enterprise doesn’t just engage in global trade or expand globally,” says Chery Group Chairman Yin Tongyue. “It must adopt a global business philosophy, bear global responsibilities, and make value contributions worldwide.” Chery is committed to becoming a “contributor” to global well-being, embedding sustainable development across its industry chain and working with international public welfare organizations and individuals to continuously explore new paradigms and models of ESG development.

Chery has made significant strides in ESG by actively fulfilling its corporate responsibilities. In children’s education, Chery has partnered with UNICEF to support nearly 40 million children globally in receiving quality education by 2023, with projects in Mexico, South Africa, Turkey, and China. In environmental protection, Chery has formally signed a global cooperation project with International Union for Conservation of Nature (IUCN), making it the largest global corporate partnership of IUCN at present. Together, they aim to support the conservation, restoration, and sustainable management of 10 million hectares of forests, grasslands, wetlands, and marine ecosystems to promote biodiversity and create a more sustainable, greener natural environment.

To expand its global ESG influence, Chery officially announced the formation of the “Chery Global ESG Community” at this year’s Chery International User Summit. This community will bring together stakeholders, including global customers, distributors, media, and public welfare organizations, to implement ESG practices worldwide.

Looking ahead, Chery will remain steadfast in fulfilling its responsibilities and duties as a global corporate citizen, harnessing global wisdom and uniting industry strength to reshape the automotive ecosystem. Chery is dedicated to offering a diverse range of products and an enriching driving experience, building a beautiful ecological future together with its users.

In the new era of advocating green travel and global connectivity, Chery continues to showcase its upward momentum and youthful vitality through concrete actions. Adhering to “innovation, green, and sharing,” Chery exemplifies the responsibility and commitment of Chinese enterprises on a global scale, spreading love and responsibility to every corner of the world.

Media Contact
Company Name: Chery Automobile
Contact Person: Kara Wang
Email: Send Email
State: Wuhu
Country: China
Website: https://www.cheryinternational.com/

QuickPR Launches New AI-Driven Features for Rapid Press Coverage & Enhanced Accessibility

QuickPR Launches New AI-Driven Features for Rapid Press Coverage & Enhanced Accessibility
Delivering Speed, Simplicity, and Top Publications in a Click

QuickPR, the leading platform for efficient, high-impact PR solutions, today announced its latest suite of updates designed to streamline the press release process. With the introduction of “AI Magic,” QuickPR enables users to generate fully crafted press articles and even recommends high-ranking publications tailored to their needs. This update underscores QuickPR’s commitment to revolutionizing the way brands gain media visibility by enhancing usability, efficiency, and access to top-tier media outlets.

Seamless AI Integration for Smarter PR

With the new AI Magic feature, QuickPR allows users to create polished PR articles in seconds. By entering a few key details, users can instantly receive a press release draft that reflects their brand’s story and goals. The AI engine also suggests the best-suited publications, ensuring that each release reaches the ideal audience and achieves maximum impact.

“Our vision has always been to make PR accessible, efficient, and impactful for every business, regardless of size,” shared Akhilendra Sahu, founder of QuickPR. “With AI Magic and our other new features, we’ve streamlined the PR process into three simple steps, making top-level press coverage achievable in record time.”

Enhanced User Experience & Support Options

The latest updates also focus on user experience and support. QuickPR has added a new search bar to make finding the right publication easier than ever. Users simply search, create or upload their articles, place an order, and get live links within 24 hours.

In addition to these enhancements, QuickPR has overhauled its registration process to make signing up even simpler. Users can now access expanded support options, including Telegram, WhatsApp, and live chat, to ensure they receive assistance when needed. New payment options such as Crypto, Stripe, PayPal, and WebMoney make the platform even more accessible for global clients.

About QuickPR

QuickPR provides a streamlined platform that makes high-impact PR accessible to businesses and professionals at any scale. With an array of easy-to-use tools, AI-generated content options, and a network of top-tier publications, QuickPR ensures brands can achieve media coverage quickly, effectively, and affordably.

For more information, visit www.app.quickpr.co.

Media Contact
Company Name: QuickPR
Contact Person: Akhilendra Sahu
Email: Send Email
Country: United States
Website: https://quickpr.co

Austech Mobile Mechanics Offers 24/7 Roadside Assistance Across Sydney

Austech Mobile Mechanics Offers 24/7 Roadside Assistance Across Sydney
The auto experts now provide 24/7 roadside assistance across Sydney, delivering quick, expert help with breakdowns, tyre repairs, and more, day or night.

Sydney, NSW – November 14, 2024 – Austech Mobile Mechanics, a leading provider of on-demand automotive services, offers comprehensive 24/7 roadside assistance service across Sydney. By providing timely, convenient, and professional assistance, Austech is now better equipped than ever to address vehicle issues, keeping drivers safe and back on the road with minimal delay.

Sydney-roadside-rescue

With an experienced team of certified mechanics, the company offers an impressive range of services designed to assist drivers in distress, no matter the time or place. The company’s 24/7 service includes emergency help with breakdowns, battery issues, flat tyres, and more. Austech’s Mobile Mechanic Sydney service ensures that help is always just a call away, providing prompt and professional aid to motorists wherever they are in the Sydney area.

Austech’s Sydney roadside rescue service is equipped to tackle a variety of issues by offering a range of services including fixing starting troubles, unlocking car doors, battery service, jump start, replacing flat tyres, emergency fuel service, towing service, and more.

“Our professionals are experienced and trusted and provide any emergency repairs you may need. We can perform same-day service, and our technicians will turn up at your location fully equipped. We use only premium tools and parts and aim for the highest quality and standards,” a spokesperson said.

In addition to emergency roadside assistance, Austech Mobile Mechanics also provides comprehensive pre purchase inspection Sydney services. These inspections, conducted by highly qualified professionals, help prospective car buyers make informed decisions by identifying potential issues before purchase. By offering on-site inspections throughout Sydney, Austech makes it easier for customers to verify a vehicle’s condition without hassle or inconvenience.

One of the most common reasons for roadside calls is a flat or damaged tyre. Austech’s flat tyre repair service is designed to address this issue quickly and efficiently. Whether it’s a puncture, worn tread, or a blowout, Austech’s mobile tyre service provides quick replacement or repair on the spot, so drivers can resume their journey safely. Vehicle owners shall call 1800-283-488.

“Our professionals are fully equipped, trained, and experienced to provide you with a reliable car service that protects the manufacturer warranty of your car. With our mobile service, we can come to your place, thus saving time and money,” the spokesperson said.

Austech Mobile Mechanics prides itself on customer satisfaction and high-quality service. By combining technical expertise with a dedication to safety and convenience, Austech has become a trusted name for roadside assistance and mobile repairs throughout Sydney.

Their mobile mechanic in Sydney uses only manufactured-recommended parts and offer up to 12 months warranty on new or re-conditioned parts. They have over 20 years of experience and has served over 1000 happy customers with a 100% satisfaction rate.

About Company:

Austech Mobile Mechanics offers a wide range of automotive repairs and maintenance round the clock. To know more, visit https://www.austechmechanic.com.au/

Media Contact
Company Name: Austech Mobile Mechanics
Contact Person: Sam Jamous
Email: Send Email
Phone: 1800 283 488
City: Chester Hill, Sydney
State: NSW
Country: Australia
Website: https://www.austechmechanic.com.au/

Future Electronics and Renesas Host Interactive Workshop on the RA8D1 MCU

Future Electronics and Renesas Host Interactive Workshop on the RA8D1 MCU
Future Electronics and Renesas will host an interactive workshop in Istanbul on November 28, which aims to educate attendees on how to use the RA8D1 microcontroller unit (MCU) for graphics and edge AI applications.

Istanbul, Turkey – November 14, 2024 – Future Electronics, a global leader in electronics components distribution, has partnered with Renesas to offer a hands-on workshop on November 28th in Istanbul, Türkiye. The workshop will provide developers with the necessary tools to advance their skills in microcontroller unit (MCU) design using the RA8D1 microcontroller.

With help from Future Electronics and Renesas representatives, developers will learn how to use Renesas’ new RA8D1, a 32-bit graphics-enabled Arm® Cortex® M85 MCU from Renesas. Designed for use in both graphics and Vision AI applications, the RA8D1 features TFT-LCD control, 2D drawing capabilities, and advanced memory options.

The workshop will first help participants launch their first MCU project using the Renesas Flexible Software Package (FSP), scalable across the RA family of Arm MCUs. Attendees will then work alongside Future Electronics and Renesas representatives to launch their first GUI on a touch screen, using the 32-bit graphics-enabled MCU. Finally, participants will be taught how to access and use the Light and Versatile Graphics Library (LVGL). EK-RA8D1 evaluation kits will be provided.

In an effort to provide attendees with scalable skills for graphics and edge AI, Future Electronics will showcase two advanced software tools: Embedded Wizard (a tool for creating platform-independent and high-performance GUIs) and Edge Impulse (the leading development platform for machine learning on edge devices).

For more information about the Seminar and to register, visit the link below:

https://futureelec.wufoo.com/forms/p4jo9we1606v2v/

Future Electronics remains committed to empowering engineers with the expertise to leverage the latest MCU technology, driving forward industry innovation in both graphics and AI.

About Future Electronics:

Founded in 1968, Future Electronics is a global leader in the electronic components industry. Future Electronics’ award-winning customer service, global supply chain programs and industry-leading engineering design services have made the company a strategic partner of choice.

Headquartered in Montreal, Canada, Future Electronics operates in 159 offices across 44 countries with over 5,000 employees. Its worldwide presence powers the company’s outstanding service and efficient, comprehensive global supply chain solutions. Future Electronics is globally integrated and supported by one IT infrastructure which provides real-time inventory availability and enables fully integrated operations, sales and marketing services worldwide. In 2024, Future became a WT Microelectronics company, now dual-headquartered in both Montreal, Canada and Taipei City, Taiwan.

Future Electronics’ mission is always to Delight the Customer®. For more information visit www.FutureElectronics.com.

Media Contact
Company Name: Future Electronics
Contact Person: Jamie Singerman
Email: Send Email
Phone: 514-694-7710
Address:237 Hymus Boulevard
City: Pointe Claire
State: Quebec
Country: Canada
Website: https://www.futureelectronics.com/

Epidermolysis Bullosa Market Size in the 7MM is ~USD ~1,700 million in 2023, estimated DelveInsight

DelveInsight’s “Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast- 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Epidermolysis Bullosa market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

The Epidermolysis Bullosa Market is an evolving segment of the global healthcare landscape, driven by the increasing Epidermolysis Bullosa prevalence of the disorder and the continuous development of innovative treatment options. The Epidermolysis Bullosa Market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

 

Discover Key Insights into the Epidermolysis Bullosa Market with DelveInsight’s In-Depth Report @ Epidermolysis Bullosa Market Size

 

Key Takeaways from the Epidermolysis Bullosa Market Report

  • In November 2024:- TWi Biotecnology Inc.- An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study].
  • In November 2024:- Holostem Terapie Avanzate s.r.l.- Multicentre, Open-label, Uncontrolled, Pivotal Clinical Trial to Confirm the Efficacy and Safety of Autologous Fibrin-cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa.
  • The United States contributed to the Epidermolysis Bullo’s highest prevalent cases, accounting for ~65% of the 7MM in 2023. Whereas EU4 and the UK, and Japan accounted for around 30% and ~5% of the total population share, respectively, in 2023.
  • Among the EU4 countries and the UK, the United Kingdom accounted for the largest number of Epidermolysis Bullosa cases, followed by Germany, whereas Spain accounted for the lowest number of cases in 2023.
  • According to DelveInsight estimates, in the United States, there were around 18,000, 1,450, and 8,500 cases of Epidermolysis Bullosa simplex, junctional Epidermolysis Bullosa, and dystrophic Epidermolysis Bullosa, respectively, in 2023.
  • The leading Epidermolysis Bullosa Companies such as Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics and others.
  • Promising Epidermolysis Bullosa Therapies such as Oleogel-S10, SD-101 dermal cream (3%), Diacerein 1% Ointment, and others

 

Stay ahead in the Epidermolysis Bullosa Therapeutics Market with DelveInsight’s Strategic Report @ Epidermolysis Bullosa Market Outlook

 

Epidermolysis Bullosa Epidemiology

  • Total Epidermolysis Bullosa prevalent cases
  • Total Epidermolysis Bullosa diagnosed prevalent cases
  • Epidermolysis Bullosa Gender-specific cases
  • Epidermolysis Bullosa Age-specific cases
  • Epidermolysis Bullosa Type-specific cases

 

Download the report to understand which factors are driving Epidermolysis Bullosa epidemiology trends @ Epidermolysis Bullosa Prevalence

 

Epidermolysis Bullosa Marketed Drugs

  • VYJUVEK (beremagene geperpavec): Krystal Biotech

B-VEC is a non-invasive, topical, redosable gene therapy designed to deliver two copies of the COL7A1 gene when applied directly to DEB wounds. In May 2023, VYJUVEK (beremagene geperpavec-svdt) was approved for treating patients 6 months of age or older with DEB. VYJUVEK is the first-ever redosable gene therapy and the first and only medicine approved by the FDA for treating DEB, both recessive and dominant; a healthcare professional can administer that in either a healthcare professional setting or in the home.

  • FILSUVEZ (oleogel-S10): Chiesi Farmaceutici

FILSUVEZ (oleogel-S10/birch triterpenes/formerly known as AP101) is an herbal medicinal product that contains birch triterpenes from birch bark. FILSUVEZ received a marketing authorization valid throughout the EU on 21 June 2022. FILSUVEZ gel is indicated for patients 6 months and older to treat superficial wounds associated with Junctional Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa. In February 2022, Amryt announced it received a Complete Response Letter (CRL) from the US FDA regarding its New Drug Application (NDA) for Oleogel-S10 for the treatment of the cutaneous manifestations of dystrophic and Junctional Epidermolysis Bullosa. The FDA asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in epidermolysis bullosa. In April 2023, Chiesi Farmaceutici announced the completion of the acquisition of Amryt Pharma.

 

Emerging Epidermolysis Bullosa Drug

  • EB-101: Abeona Therapeutics

EB-101 is an autologous, engineered cell therapy currently being developed to treat Recessive Dystrophic Epidermolysis Bullosa. Treatment with EB-101 involves using gene transfer to deliver the COL7A1 gene into a patient’s skin cells (keratinocytes and its progenitors) and transplanting those cells back to the patient. EB-101 is being investigated for its ability to enable normal Type VII collagen expression and to facilitate wound healing. EB-101 has the potential to be the first approved therapy for RDEB and the only durable treatment to address large chronic wounds, which are the most painful and debilitating.

  • D-Fi (dabocemagene autoficel): Castle Creek Biosciences

D-Fi, also known as FCX-007 (dabocemagene autoficel), is an autologous gene therapy candidate to treat dystrophic Epidermolysis Bullosa (DEB), a progressive, devastatingly painful, and debilitating, rare genetic skin disorder. D-Fi is currently in Phase III clinical development for the localized treatment of chronic wounds in individuals with Recessive Dystrophic Epidermolysis Bullosa. The clinical study plan includes a multi-center, within-patient randomized, controlled, open-label study of D-Fi and builds on data reported from the Phase I/II clinical trial.

 

Get In-Depth Knowledge on Epidermolysis Bullosa Market Trends and Forecasts with DelveInsight @ Epidermolysis Bullosa Treatment Market

 

Epidermolysis Bullosa Market Outlook

There is no cure for any of the subtypes of Epidermolysis Bullosa resulting from different mutations, and current therapy only focuses on managing wounds and pain. Novel effective therapeutic approaches are therefore urgently required. Management of Epidermolysis Bullosa focuses on supportive and wound care, prevention of blistering and infection, symptomatic relief of pain and itch, and prevention, monitoring, and treatment of complications. Wound care remains the cornerstone of treatment and includes the use of semi-occlusive, protective bandages to the affected area to decrease pain and reduce and prevent blistering, scarring, and infection. Dressing changes and wound care can be time-consuming and expensive, making them burdensome to patients and caregivers.

 

Scope of the Epidermolysis Bullosa Market Report

  • Coverage- 7MM
  • Epidermolysis Bullosa Companies- Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics and others
  • Epidermolysis Bullosa Therapies- Oleogel-S10, SD-101 dermal cream (3%), Diacerein 1% Ointment, and others
  • Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa Market Drivers and Barriers
  • Epidermolysis Bullosa Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Epidermolysis Bullosa Drugs in development @ Epidermolysis Bullosa Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of Epidermolysis Bullosa (EB)

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Epidermolysis Bullosa Market Overview at a Glance

7. Epidermolysis Bullosa (EB): Disease Background and Overview

8. Treatment and Management of Epidermolysis Bullosa

9. Guidelines

10. Epidemiology and Patient Population of 7MM

11. Patient Journey

12. Marketed Drugs

13. Emerging Drugs

14. Epidermolysis Bullosa: 7MM Analysis

15. Unmet needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epidermolysis Bullosa Market Size in the 7MM is ~USD ~1,700 million in 2023, estimated DelveInsight

Infectious Disease Diagnostics Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and Forecast

“The major players operating in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US)”
North America held the predominant portion of the infectious disease diagnostics market. The infectious disease diagnostics market in North America is well-established, with the US being a major market in this region.

 Infectious Disease Diagnostics Market in terms of revenue was estimated to be worth $21.4 billion in 2023 and is poised to reach $31.5 billion by 2028, growing at a CAGR of 8.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Market growth is largely driven by the rising prevalence of infectious diseases and the increasing funding for R&D in disease diagnostics. The rising incidence of infectious diseases worldwide creates a substantial demand for effective diagnostic tools. As the global healthcare landscape grapples with the challenges posed by infectious agents, there is a heightened emphasis on developing advanced diagnostic technologies to enable timely and accurate detection.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

In 2022, the reagents, kits, and consumables segment held the largest share of the infectious disease diagnostics market by product & service segment.

The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services based on product & service. The reagents, kits, and consumables segment dominated the infectious disease diagnostics market in 2022. The requirement of reagents, kits, and consumables in large numbers compared to instruments is the main factor contributing to the large share of this segment. Unlike instruments, reagents, kits, and consumables require repeat purchases, which results in stable demand among end users.

The blood, serum, and plasma segment held the largest share of the infectious disease diagnostics market by sample type segment in 2022.

Based on sample type, the infectious disease diagnostics market has been segmented into blood, serum, and plasma, urine, and other sample types. In 2022, the blood, serum, and plasma segment accounted for the largest share of the infectious disease diagnostics market, by sample type. These sample types provide a rich and diverse pool of infectious disease diagnostic information. They contain circulating DNA, RNA, proteins, and other biomarkers that carry valuable insights into various diseases and conditions. This wealth of information enables healthcare professionals to make accurate diagnoses, monitor disease progression, and personalize treatment decisions.

North America is the largest regional market for infectious disease diagnostics market.

The market for infectious disease diagnostics has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the predominant portion of the infectious disease diagnostics market. The infectious disease diagnostics market in North America is well-established, with the US being a major market in this region. This dominance can be attributed to various factors, including advanced healthcare infrastructure, a high prevalence of infectious diseases, and significant investments in diagnostic technologies.

Infectious Disease Diagnostics Market Dynamics:

Drivers:

  1. Rising prevalence of infectious diseases

Restraints:

  1. Unfavorable reimbursement scenario

Opportunities:

  1. Increased growth opportunities in emerging economies

Challenge:

  1. Operational barriers and shortage of skilled laboratory technicians

Key Market Players of Infectious Disease Diagnostics Industry:

The major players operating in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Revvity (US), QIAGEN (Netherlands), Seegene Inc. (South Korea), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QuidelOrtho Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech (Ireland), Chembio Diagnostics, Inc. (US), Co-Diagnostics, Inc. (US), ELITech Group (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Vela Diagnostics (Singapore), and Uniogen Oy (Finland).

The break-up of the profile of primary participants in the infectious disease diagnostics market:

  • By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
  • By Designation: C-level – 27%, D-level – 18%, and Others – 55%
  • By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=116764589

Infectious Disease Diagnostics Market Recent Developments:

  • In January 2023, Thermo Fisher Scientific Inc. (US) launched its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit.
  • In July 2022, Roche launched Elecsys HCV Duo, an immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
  • In September 2022, Siemens Healthineers released its CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Test.
  • In December 2021, Roche completed a purchase agreement with TIB Molbiol (Germany) to expand the PCR-test portfolio in the fight against new infectious diseases.
  • In February 2020, Cepheid collaborated with Sherlock Biosciences (US). This collaboration between the two companies aimed to explore the development of new cutting-edge molecular diagnostic tests for infectious diseases leveraging CRISPR technology.

Infectious Disease Diagnostics Market – Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising prevalence of infectious diseases, Rising focus on R&D and funding in infectious disease diagnostic products, Growing awareness for early disease diagnosis in emerging economies, Adoption of new and advanced technologies for infectious disease diagnosis, Shift in focus from centralized laboratories to decentralized PoC testing centers), opportunities (Increased growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (Changing regulatory landscape, Operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the infectious disease diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), and Thermo Fisher Scientific Inc. (US), among others in the infectious disease diagnostics market strategies.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/infectious-disease-diagnostics-market-116764589.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Infectious Disease Diagnostics Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and Forecast

Digital Pathology Market to Register 7.8% CAGR by 2031, Amidst Growing Demand for Efficient Diagnostic Tools

“Digital Pathology Market”
The global Digital Pathology Market is projected to grow from USD 1.13 billion in 2023 to USD 2.07 billion by 2031, at a CAGR of 7.8%. Key drivers include advancements in software (integrated, standalone, cloud-based), scanners, and applications in drug development, disease diagnosis, and research across human and veterinary pathology.

Global Digital Pathology Market will reach a value of USD 2067.36 million by 2031, with a CAGR of 7.8% during the forecast period (2024-2031). More rapid diagnostic technologies have been increasing in demand as cancer cases rise and the need for streamlined workflows continues to grow. With the remarkable support from major market players, other factors that are contributing to growth of the market include increased telepathology application, investments in health care and precision medicine and drug discovery. The global digital pathology market has been expanding due to a growing acceptance of healthcare IT solutions. To cut costs, enhance workflows, release resources, and promote useful information exchange businesses are implementing them more often now. 

To Learn More About This Report, Request a Free Sample Copy – https://www.skyquestt.com/sample-request/digital-pathology-market

Industry Giants and Rising Stars are Shaping Future of Digital Pathology 

Innovation and strategic alliances are driving a dynamic competitive landscape in the global digital pathology market. Leading companies with cutting-edge imaging technologies and AI integration include Philips Healthcare, Leica Biosystems, and Roche. Recently established companies, such as Proscia and PathAI employ superior machine learning techniques to enhance the accuracy of their identification. Old companies are focusing on diversification of product lines and forming alliances to increase their market share. The competition becomes stiffer as the businesses explore new markets as well as conducting research and development to satisfy the rising demand for efficient and distant diagnostic solutions. 

Exploring Competitive Dynamics and Market Shifts 

The global digital pathology market has become a battlefield where both innovative entrants and established players are active participants in the competitive arena. Leading companies like Philips Healthcare, Leica Biosystems, and Roche are setting the standard for diagnostic accuracy when it comes to technology that utilizes advanced imaging methods along with robust AI integration. Emerging firms like PathAI and Proscia are making their mark in the fields of machine learning that endorse improved precision during diagnoses. 

Such companies are enhancing rivalry by broadening their assortment of products and engaging in collaborative effort to tap the potentialities of emerging markets. This dynamic background similarly reflects the global movement towards efficient remote diagnostic options. 

Get Customization on this Report for Specific Research Solutions: https://www.skyquestt.com/speak-with-analyst/digital-pathology-market

Unraveling Competitive Dynamics of Digital Pathology Through Strategic Acquisitions 

Aperio GT 450 digital slide scanner from Leica Biosystems and PathXL purchase by Philips Healthcare show how well-established players are improving their technology in the highly competitive global digital pathology market. To improve diagnostic accuracy, Roche has integrated artificial intelligence (AI) into its uPath enterprise software. AI-driven platforms are being used by up-and-coming companies like PathAI and Proscia to push boundaries. PathAI, for example, has partnered with major cancer centres to improve diagnosis algorithms. Dynamic attracts buyer, therefore two types of it (business level and overall) are differentiated. USA-based McDonald’s is among the largest fast-food chains in the globe that have shown such dynamic growth despite its competitors. However, this is contrary to business ideas where a large fast-food chain has marginal growth rate which can even lead to it being termed as a dying industry. 

Digital Pathology Market Segmental Analysis:  

Product 

Software 

Device 

Storage Systems 

Type 

Human pathology 

Veterinary pathology 

End user 

Pharmaceutical 

Biotechnology 

Application

Drug Discovery & Development

Academic Research

Disease Diagnosis

Take Action Now: Secure Your Digital Pathology Industry Today – https://www.skyquestt.com/buy-now/digital-pathology-market

Digital Pathology Industry Top Player’s Company Profiles: 

Philips Healthcare (Netherlands)

Roche Diagnostics (Switzerland)

Hamamatsu Photonics (Japan)

3DHISTECH (Hungary)

GE Healthcare (US)

Apollo Enterprise Imaging (US)

Olympus Corporation (Japan)

Mikroscan Technologies (US)

Inspirata (US)

PerkinElmer (US)

Huron Digital Pathology (Canada)

Sectra AB (Sweden)

PathAI (US)

Indica Labs (US)

F. Hoffmann-La Roche (Switzerland)

Nikon Corporation (Japan)

Danaher Corporation (US)

Visiopharm (Denmark)

Densitas (Canada)

Objective Pathology (US)

QPath (US)

Navigating Driving Growth and Competition in Global Digital Pathology Market 

In the global digital pathology market rapid growth is due to the increasing cancer incidence, hence the demand for quick diagnostic risen, as well as an emphasis on workflow efficiency. Companies like Philips Healthcare, Leica Biosystems and Roche are developing the sector through Artificial Intelligence (AI) algorithms and modern imaging technologies. Meanwhile, new startups like Proscia and PathAI are using advanced machine learning to redefine diagnostic accuracy. The level of competition increases as these businesses broaden their portfolios and establish strategic partnerships. Fuelled by continuous industrial investments and technical breakthroughs, this dynamic environment reflects a broader trend towards greater remote diagnostics. 

Read Digital Pathology Industry Report Today – https://www.skyquestt.com/report/digital-pathology-market

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/digital-pathology-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Digital Pathology Market to Register 7.8% CAGR by 2031, Amidst Growing Demand for Efficient Diagnostic Tools